A Phase 2 interventional study of Daratumumab and Vincristine in Precursor Cell Lymphoblastic Leukemia-Lymphoma, sponsored by Janssen Research & Development, LLC. Completed at 53 sites in 10 countries. Open to participants aged 1 Year to 30 Years. Per ClinicalTrials.gov, last updated 2025-05-25.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States — 171 open to participants now, 277 under way, 13 of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States.
Among the 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States, this one is the 485th largest by enrollment of the 1,269 interventional ones that give a count, is one of 39 that started in 2018, is one of 426 in phase 2, and was the 1,186th registered.
2,585 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 473 are open to participants now.
Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →171 of the 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States are open now. Recruiting first, the newest first:
Wake Forest University Health Sciences · Sites in United States
Ages 18+
St. Jude Children's Research Hospital · Sites in United States
Ages 8–18 · Healthy volunteers
National Cancer Institute (NCI) · Sites in United States
Ages 1–25
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
Children's Hospital of Orange County · Sites in United States
Ages 0–18
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 370 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (69%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.
This study: 1 Year to 30 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,545 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 653 · Phase 2 593 · Phase 3 107 · Phase 4 10
First in 1984; this study’s year is marked. 39 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 47 is above the median of 40 across 1,952 interventional studies indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Median enrollment 35 across the 1,269 interventional studies, 110 across the 154 observational. Of the 1,180 that completed or were terminated, 437 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
213 of 1,545 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
Johnson & Johnson has 4 studies filed under Precursor Cell Lymphoblastic Leukemia-Lymphoma — fewer than ten, so there is no comparison to draw.
96 of the studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03020030Phase 3Dana-Farber Cancer InstituteTreatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents | 2026-11-30 |
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
| NCT04851717Phase 3Acacia Pharma LtdInvestigation of Remimazolam in Children Undergoing Sedation for Medical Procedures | 2027-10 |
| NCT03104491Leland MethenyInotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia | 2026-11 |
| NCT06795126Nationwide Children's HospitalLittle NIRVANA for Pediatric Pain and Anxiety | 2026-11-30 |
Add all 96 to your calendar (.ics) → With an account.
Among the 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy of daratumumab in addition to standard chemotherapy in pediatric participants with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LL) and T-cell ALL/LL as measured by the complete response (CR) rate.
Screening for eligible participants will be performed within 21 days before administration of the study drug. Participants with B-cell ALL/LL will receive treatment until disease progression, unacceptable toxicity or achievement of CR followed by hematopoietic stem cell transplant (HSCT). Participants with T cell ALL/LL will receive treatment for up to 2 cycles. If disease progression is confirmed, then the participant will discontinue study treatment, complete the End of Treatment Visit, and enter the Posttreatment Period. For those participants who discontinue study drug prior to disease progression, disease evaluations will continue to be performed every 8 weeks until subsequent anticancer therapy is initiated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Documented acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL) as defined by the criteria below:
Adequate hematology laboratory values at Cycle 1 Day 1 pre-dosing defined as follows:
Adequate liver function prior to enrollment defined as:
Exclusion Criteria:
Has either of the following:
Any one of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cohort 1 will include participants with B cell ALL/LL in second or greater relapse or refractory to at least 2 prior induction regimens. Participant will receive daratumumab in combination with vincristine and prednisone.
Drug: Daratumumab · Drug: Vincristine · Drug: Prednisone
Cohort 2 will include participants with T-cell ALL/LL in first relapse or refractory to at least 1 prior induction/consolidation regimen. Participant will receive daratumumab in combination with vincristine, prednisone, doxorubicin and peg-asparaginase in Cycle 1 and daratumumab in combination with cyclophosphamide, cytarabine, 6- mercaptopurine and methotrexate in Cycle 2.
Drug: Daratumumab · Drug: Vincristine · Drug: Prednisone · Drug: Doxorubicin · Biological: Peg-asparaginase · Drug: Cyclophosphamide · Drug: Cytarabine · Drug: 6-mercaptopurine · Drug: Methotrexate
Participant will receive daratumumab 16 milligram per kilogram (mg/kg) in cohort 1 and cohort 2.
Participant will receive vincristine 1.5 milligram per meter square (mg/m\^2) in cohort 1 and cohort 2.
Participant will receive prednisone 40 mg/m\^2 in cohort 1 and cohort 2.
Participant will receive doxorubicin 60 mg/m\^2 in cohort 2.
Participant will receive peg-asparaginase 2500 units per meter square (U/m\^2) in cohort 2.
Participant will receive cyclophosphamide 1 gram per meter square (g/m\^2) once in cohort 2.
Participant will receive cytarabine 75 mg/m\^2 in cohort 2.
Participant will receive 6-mercaptopurine 60 mg/m\^2 orally daily in cohort 2.
Participant will receive methotrexate 5 g/m\^2 intravenously (IV) in cohort 2.
Cohort 1: Percentage of Participants With Complete Response (CR) for B-cell Acute Lymphoblastic Leukemia (ALL)
Complete response based on the modified National Comprehensive Cancer Network (NCCN) criteria was defined as: less than 5 percent (%) blasts in the bone marrow; no evidence of circulating blasts or extramedullary disease; full recovery of peripheral blood counts: platelets greater than (\>)100\*10\^9 cells/liter (L) and absolute neutrophil count (ANC) \>1.0\*10\^9 cells/L. This outcome measure was planned to be analyzed for specified arm only.
Time frame: Up to 2 cycles, that is, up to 56 days (each cycle of 28-days)
Cohort 2: Percentage of Participants With Complete Response (CR) for T-cell ALL
Complete response based on the modified NCCN criteria was defined as: less than 5% blasts in the bone marrow; no evidence of circulating blasts or extramedullary disease; full recovery of peripheral blood counts: platelets \>100\*10\^9 cells/L and ANC \>1.0\*10\^9 cells/L. This outcome measure was planned to be analyzed for specified arms only.
Time frame: End of Cycle 1 (that is, up to 28 days)
Overall Response Rate (ORR)
For ALL participants, ORR was defined as percentage of participants who achieved CR or CR with only partial hematological recovery(CRi) as per NCCN criteria. CR for ALL: less than 5% blasts in bone marrow; no evidence of circulating blasts or extramedullary disease; full recovery of peripheral blood counts: platelets \>100\*10\^9 cells/L and ANC \>1.0\*10\^9 cells/L. CRi for ALL: less than 5% blasts in bone marrow; no evidence of circulating blasts or extramedullary disease; partial recovery of peripheral blood counts not meeting criteria for CR. For LL participants, ORR was defined as percentage of participants who had CR or PR during or after treatment administration but prior to start of subsequent anti-cancer therapy or allogeneic hematopoietic stem cell transplant(HSCT). CR for LL: disappearance of all evidence of disease from all sites. PR for LL: decrease of \>=50% in sum of products of diameter of lesions of up to 6 of largest dominant nodes or nodal masses with no new lesions.
Time frame: Up to 4 years 4 months
Event-free Survival (EFS)
EFS was defined as the time (in months) from the date of first treatment to the first documented treatment failure (that is \[ie\], disease progression) or date of relapse from CR or death due to any cause, whichever occurred first. Per NCCN criteria, relapse from CR is defined as: reappearance of leukemia blasts in the peripheral blood or \>5% blasts in the bone marrow; reappearance of extramedullary disease or new extramedullary disease. Progressive disease: increase of at least 25% in the absolute number of circulating peripheral or bone marrow blasts, or development of new extramedullary disease. Kaplan-Meier method was used for the analysis.
Time frame: Up to 4 years 4 months
Relapse-free Survival (RFS)
RFS was defined as the time (in months) from CR to relapse from CR, or disease progression or death due to any cause, whichever occurred first. For ALL, as per NCCN criteria, relapse from CR is defined as: reappearance of leukemia blasts in the peripheral blood or \>5% blasts in the bone marrow, or reappearance of extramedullary disease or new extramedullary disease. Progressive disease: increase of at least 25% in absolute number of circulating peripheral or bone marrow blasts, or development of new extramedullary disease. Kaplan-Meier method was used for analysis.
Time frame: Up to 4 years 4 months
Overall Survival (OS)
OS was defined as the time (in months) from the date of first study drug administration to the date of death due to any cause. Kaplan-Meier method was used for the analysis. Participants who died after consent withdrawal were considered as having an OS event.
Time frame: Up to 4 years 4 months
Minimal Residual Disease (MRD) Negative Rate
MRD negative rate was defined as the percentage of participants who were considered MRD negative after MRD testing by bone marrow aspirate at any timepoint after first study treatment administration and before disease progression or starting subsequent anti-cancer therapy or allogeneic hematopoietic stem cell transplant (HSCT). MRD negative was defined as less than (\<) 0.01% abnormal population counts to nucleated mononuclear cells when measured by flow cytometry.
Time frame: Up to 4 years 4 months
Percentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant (HSCT)
Percentage of participants who received an allogeneic HSCT after treatment with daratumumab were reported.
Time frame: Up to 4 years 4 months
Maximum Observed Serum Concentration (Cmax) of Daratumumab
Cmax was defined as maximum observed serum concentration of daratumumab.
Time frame: Cohort 1: B-cell ALL: End of infusion (EOI) on Day 1 of Cycle 2; Cohort 2: T-cell ALL (1-17 years): EOI on Day 22 of Cycle 2; Cohort 2: T-cell ALL (18-30 years): EOI on Day 1 of Cycle 2; Cohort 2: T-cell LL (1-30 years): EOI on Day 22 of Cycle 2
Minimum Observed Serum Concentration (Cmin) of Daratumumab
Cmin was defined as minimum observed serum concentration of daratumumab.
Time frame: Cohort 1: B-cell ALL: Predose on Day 1 of Cycle 2; Cohort 2: T-cell ALL (1-17 years): Predose on Day 22 of Cycle 2; Cohort 2: T-cell ALL (18-30 years): Predose on Day 1 of Cycle 2; Cohort 2: T-cell LL (1-30 years): Predose on Day 22 of Cycle 2
Number of Participants With Anti-daratumumab Antibodies
Number of participants with anti-daratumumab antibodies was reported.
Time frame: Up to 4 years 4 months
Concentration of Daratumumab in Cerebrospinal Fluid (CSF)
Concentration of daratumumab in CSF was reported. '0' in the number analyzed field signifies that none of the participants were available for the analysis at the specified time points.
Time frame: Pre-dose on Cohort 1: Cycles 1 and 2: Day 1; Cohort 2: Cycle 1 Day 1 and Day 15 and Cycle 2 Day 2 and Day 15
| Milestone | Cohort 1: B-cell ALL (1-17 Years) | Cohort 2: T-Cell ALL (1-17 Years) | Cohort 2: T-Cell ALL (18-30 Years) | Cohort 2: T-Cell Lymphoblastic Leukemia (LL) (1-30 Years) |
|---|---|---|---|---|
| Started | 7 | 24 | 5 | 10 |
| Completed | 7 | 24 | 4 | 10 |
| Not completed | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 |
Complete response based on the modified National Comprehensive Cancer Network (NCCN) criteria was defined as: less than 5 percent (%) blasts in the bone marrow; no evidence of circulating blasts or extramedullary disease; full recovery of peripheral blood counts: platelets greater than (\>)100\*10\^9 cells/liter (L) and absolute neutrophil count (ANC) \>1.0\*10\^9 cells/L. This outcome measure was planned to be analyzed for specified arm only.
| Percentage of participants | Cohort 1: B-cell ALL (1-17 Years) |
|---|---|
| Cohort 1: Percentage of Participants With Complete Response (CR) for B-cell Acute Lymphoblastic Leukemia (ALL) | 0 (NA to NA) |
Complete response based on the modified NCCN criteria was defined as: less than 5% blasts in the bone marrow; no evidence of circulating blasts or extramedullary disease; full recovery of peripheral blood counts: platelets \>100\*10\^9 cells/L and ANC \>1.0\*10\^9 cells/L. This outcome measure was planned to be analyzed for specified arms only.
| Percentage of participants | Cohort 2: T-Cell ALL (1-17 Years) | Cohort 2: T-Cell ALL (18-30 Years) | Cohort 2: T-Cell Lymphoblastic Leukemia (LL) (1-30 Years) |
|---|---|---|---|
| Cohort 2: Percentage of Participants With Complete Response (CR) for T-cell ALL | 41.7 (24.6 to 60.3) | 60.0 (18.9 to 92.4) | 30.0 (8.7 to 60.7) |
For ALL participants, ORR was defined as percentage of participants who achieved CR or CR with only partial hematological recovery(CRi) as per NCCN criteria. CR for ALL: less than 5% blasts in bone marrow; no evidence of circulating blasts or extramedullary disease; full recovery of peripheral blood counts: platelets \>100\*10\^9 cells/L and ANC \>1.0\*10\^9 cells/L. CRi for ALL: less than 5% blasts in bone marrow; no evidence of circulating blasts or extramedullary disease; partial recovery of peripheral blood counts not meeting criteria for CR. For LL participants, ORR was defined as percentage of participants who had CR or PR during or after treatment administration but prior to start of subsequent anti-cancer therapy or allogeneic hematopoietic stem cell transplant(HSCT). CR for LL: disappearance of all evidence of disease from all sites. PR for LL: decrease of \>=50% in sum of products of diameter of lesions of up to 6 of largest dominant nodes or nodal masses with no new lesions.
| Percentage of participants | Cohort 1: B-cell ALL (1-17 Years) | Cohort 2: T-Cell ALL (1-17 Years) | Cohort 2: T-Cell ALL (18-30 Years) | Cohort 2: T-Cell Lymphoblastic Leukemia (LL) (1-30 Years) |
|---|---|---|---|---|
| Overall Response Rate (ORR) | 14.3 (0.7 to 52.1) | 83.3 (65.8 to 94.1) | 80.0 (34.3 to 99.0) | 50.0 (22.2 to 77.8) |
EFS was defined as the time (in months) from the date of first treatment to the first documented treatment failure (that is \[ie\], disease progression) or date of relapse from CR or death due to any cause, whichever occurred first. Per NCCN criteria, relapse from CR is defined as: reappearance of leukemia blasts in the peripheral blood or \>5% blasts in the bone marrow; reappearance of extramedullary disease or new extramedullary disease. Progressive disease: increase of at least 25% in the absolute number of circulating peripheral or bone marrow blasts, or development of new extramedullary disease. Kaplan-Meier method was used for the analysis.
| Months | Cohort 1: B-cell ALL (1-17 Years) | Cohort 2: T-Cell ALL (1-17 Years) | Cohort 2: T-Cell ALL (18-30 Years) | Cohort 2: T-Cell Lymphoblastic Leukemia (LL) (1-30 Years) |
|---|---|---|---|---|
| Event-free Survival (EFS) | 1.1 (0.9 to 2.1) | 8.9 (5.3 to NA) | 10.3 (2.6 to NA) | 2.9 (1.3 to 4.9) |
RFS was defined as the time (in months) from CR to relapse from CR, or disease progression or death due to any cause, whichever occurred first. For ALL, as per NCCN criteria, relapse from CR is defined as: reappearance of leukemia blasts in the peripheral blood or \>5% blasts in the bone marrow, or reappearance of extramedullary disease or new extramedullary disease. Progressive disease: increase of at least 25% in absolute number of circulating peripheral or bone marrow blasts, or development of new extramedullary disease. Kaplan-Meier method was used for analysis.
| Months | Cohort 1: B-cell ALL (1-17 Years) | Cohort 2: T-Cell ALL (1-17 Years) | Cohort 2: T-Cell ALL (18-30 Years) | Cohort 2: T-Cell Lymphoblastic Leukemia (LL) (1-30 Years) |
|---|---|---|---|---|
| Relapse-free Survival (RFS) | — | 19.4 (5.3 to NA) | 9.4 (3.6 to NA) | NA (1.8 to NA) |
OS was defined as the time (in months) from the date of first study drug administration to the date of death due to any cause. Kaplan-Meier method was used for the analysis. Participants who died after consent withdrawal were considered as having an OS event.
| Months | Cohort 1: B-cell ALL (1-17 Years) | Cohort 2: T-Cell ALL (1-17 Years) | Cohort 2: T-Cell ALL (18-30 Years) | Cohort 2: T-Cell Lymphoblastic Leukemia (LL) (1-30 Years) |
|---|---|---|---|---|
| Overall Survival (OS) | 3.2 (1.0 to 3.6) | 10.9 (6.7 to NA) | 12.0 (4.5 to NA) | 4.2 (1.7 to 5.6) |
MRD negative rate was defined as the percentage of participants who were considered MRD negative after MRD testing by bone marrow aspirate at any timepoint after first study treatment administration and before disease progression or starting subsequent anti-cancer therapy or allogeneic hematopoietic stem cell transplant (HSCT). MRD negative was defined as less than (\<) 0.01% abnormal population counts to nucleated mononuclear cells when measured by flow cytometry.
| Percentage of participants | Cohort 1: B-cell ALL (1-17 Years) | Cohort 2: T-Cell ALL (1-17 Years) | Cohort 2: T-Cell ALL (18-30 Years) | Cohort 2: T-Cell Lymphoblastic Leukemia (LL) (1-30 Years) |
|---|---|---|---|---|
| Minimal Residual Disease (MRD) Negative Rate | 0 (0 to 0) | 45.8 (28.2 to 64.2) | 20.0 (1.0 to 65.7) | 50.0 (22.2 to 77.8) |
Percentage of participants who received an allogeneic HSCT after treatment with daratumumab were reported.
| Percentage of participants | Cohort 1: B-cell ALL (1-17 Years) | Cohort 2: T-Cell ALL (1-17 Years) | Cohort 2: T-Cell ALL (18-30 Years) | Cohort 2: T-Cell Lymphoblastic Leukemia (LL) (1-30 Years) |
|---|---|---|---|---|
| Percentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant (HSCT) | 14.3 (0.7 to 52.1) | 75.0 (56.5 to 88.5) | 60.0 (18.9 to 92.4) | 30.0 (8.7 to 60.7) |
Cmax was defined as maximum observed serum concentration of daratumumab.
| Micrograms per milliliter (mcg/mL) | Cohort 1: B-cell ALL (1-17 Years) | Cohort 2: T-Cell ALL (1-17 Years) | Cohort 2: T-Cell ALL (18-30 Years) | Cohort 2: T-Cell Lymphoblastic Leukemia (LL) (1-30 Years) |
|---|---|---|---|---|
| Maximum Observed Serum Concentration (Cmax) of Daratumumab | 494 ± 184 | 763 ± 185 | 501 ± 347 | 758 ± 157 |
Cmin was defined as minimum observed serum concentration of daratumumab.
| mcg/mL | Cohort 1: B-cell ALL (1-17 Years) | Cohort 2: T-Cell ALL (1-17 Years) | Cohort 2: T-Cell ALL (18-30 Years) | Cohort 2: T-Cell Lymphoblastic Leukemia (LL) (1-30 Years) |
|---|---|---|---|---|
| Minimum Observed Serum Concentration (Cmin) of Daratumumab | 172 ± 115 | 369 ± 105 | 172 ± 177 | 365 ± 204 |
Number of participants with anti-daratumumab antibodies was reported.
| Participants | Cohort 1: B-cell ALL (1-17 Years) | Cohort 2: T-Cell ALL (1-17 Years) | Cohort 2: T-Cell ALL (18-30 Years) | Cohort 2: T-Cell Lymphoblastic Leukemia (LL) (1-30 Years) |
|---|---|---|---|---|
| Number of Participants With Anti-daratumumab Antibodies | 0 | 0 | 0 | 0 |
Concentration of daratumumab in CSF was reported. '0' in the number analyzed field signifies that none of the participants were available for the analysis at the specified time points.
| mcg/mL | Cohort 1: B-cell ALL (1-17 Years) | Cohort 2: T-Cell ALL (1-17 Years) | Cohort 2: T-Cell ALL (18-30 Years) | Cohort 2: T-Cell Lymphoblastic Leukemia (LL) (1-30 Years) |
|---|---|---|---|---|
| Cycle 1 Day 1 predose | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Cycle 1 Day 15 predose | — | 0.907 ± 1.96 | 0.319 ± 0.203 | 0.456 ± 0.280 |
| Cycle 2 Day 1 predose | 0.573 ± 0.545 | — | — | — |
| Cycle 2 Day 2 predose | — | 0.915 ± 0.916 | 0.296 ± 0.191 | 1.23 ± 0.728 |
| Cycle 2 Day 15 predose | — | 0.934 ± 0.549 | 0.163 | 1.06 ± 0.282 |
Collected over From baseline (Day 1) up to 4 years 4 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: B-cell ALL (1-17 Years) | 7/7 (100%) | 3/7 (42.9%) | 7/7 (100%) |
| Cohort 2: T-Cell ALL (1-17 Years) | 14/24 (58.3%) | 16/24 (66.7%) | 24/24 (100%) |
| Cohort 2: T-Cell ALL (18-30 Years) | 3/5 (60%) | 4/5 (80%) | 5/5 (100%) |
| Cohort 2: T-Cell Lymphoblastic Leukemia (LL) (1-30 Years) | 8/10 (80%) | 7/10 (70%) | 10/10 (100%) |
| Event | Cohort 1: B-cell ALL (1-17 Years) | Cohort 2: T-Cell ALL (1-17 Years) | Cohort 2: T-Cell ALL (18-30 Years) | Cohort 2: T-Cell Lymphoblastic Leukemia (LL) (1-30 Years) |
|---|---|---|---|---|
| Febrile NeutropeniaBlood and lymphatic system disorders | 3/7 | 6/24 | 1/5 | 2/10 |
| PyrexiaGeneral disorders | 0/7 | 7/24 | 1/5 | 1/10 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/7 | 0/24 | 1/5 | 0/10 |
| StomatitisGastrointestinal disorders | 0/7 | 1/24 | 1/5 | 0/10 |
| PainGeneral disorders | 0/7 | 0/24 | 1/5 | 0/10 |
| CellulitisInfections and infestations | 0/7 | 1/24 | 1/5 | 0/10 |
| Septic ShockInfections and infestations | 0/7 | 2/24 | 1/5 | 0/10 |
| Weight DecreasedInvestigations | 0/7 | 0/24 | 1/5 | 0/10 |
| Decreased AppetiteMetabolism and nutrition disorders | 0/7 | 0/24 | 1/5 | 0/10 |
| DeliriumPsychiatric disorders | 0/7 | 0/24 | 1/5 | 0/10 |
| Event | Cohort 1: B-cell ALL (1-17 Years) | Cohort 2: T-Cell ALL (1-17 Years) | Cohort 2: T-Cell ALL (18-30 Years) | Cohort 2: T-Cell Lymphoblastic Leukemia (LL) (1-30 Years) |
|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 4/7 | 16/24 | 2/5 | 10/10 |
| ThrombocytopeniaBlood and lymphatic system disorders | 2/7 | 18/24 | 3/5 | 9/10 |
| ConstipationGastrointestinal disorders | 2/7 | 6/24 | 4/5 | 2/10 |
| HyperbilirubinaemiaHepatobiliary disorders | 0/7 | 7/24 | 4/5 | 4/10 |
| Blood Alkaline Phosphatase IncreasedInvestigations | 0/7 | 0/24 | 4/5 | 0/10 |
| HyponatraemiaMetabolism and nutrition disorders | 0/7 | 6/24 | 4/5 | 2/10 |
| StomatitisGastrointestinal disorders | 0/7 | 10/24 | 2/5 | 7/10 |
| PyrexiaGeneral disorders | 4/7 | 13/24 | 3/5 | 7/10 |
| NeutropeniaBlood and lymphatic system disorders | 2/7 | 15/24 | 2/5 | 6/10 |
| Abdominal PainGastrointestinal disorders | 2/7 | 12/24 | 3/5 | 4/10 |
| Age, Continuous(years) | Cohort 1: B-cell ALL (1-17 Years) | Cohort 2: T-Cell ALL (1-17 Years) | Cohort 2: T-Cell ALL (18-30 Years) | Cohort 2: T-Cell Lymphoblastic Leukemia (LL) (1-30 Years) | Total |
|---|---|---|---|---|---|
| Mean | 8.1 ± 5.01 | 9.8 ± 4.17 | 22.2 ± 2.77 | 13.5 ± 5.68 | 11.7 ± 6.03 |
| Sex: Female, Male(Participants) | Cohort 1: B-cell ALL (1-17 Years) | Cohort 2: T-Cell ALL (1-17 Years) | Cohort 2: T-Cell ALL (18-30 Years) | Cohort 2: T-Cell Lymphoblastic Leukemia (LL) (1-30 Years) | Total |
|---|---|---|---|---|---|
| Female | 4 | 10 | 0 | 1 | 15 |
| Male | 3 | 14 | 5 | 9 | 31 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1: B-cell ALL (1-17 Years) | Cohort 2: T-Cell ALL (1-17 Years) | Cohort 2: T-Cell ALL (18-30 Years) | Cohort 2: T-Cell Lymphoblastic Leukemia (LL) (1-30 Years) | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 4 | 2 | 1 | 8 |
| Not Hispanic or Latino | 4 | 16 | 3 | 7 | 30 |
| Unknown or Not Reported | 2 | 4 | 0 | 2 | 8 |
| Race (NIH/OMB)(Participants) | Cohort 1: B-cell ALL (1-17 Years) | Cohort 2: T-Cell ALL (1-17 Years) | Cohort 2: T-Cell ALL (18-30 Years) | Cohort 2: T-Cell Lymphoblastic Leukemia (LL) (1-30 Years) | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 0 | 1 |
| Asian | 0 | 1 | 1 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 1 | 0 | 1 |
| White | 5 | 18 | 2 | 8 | 33 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 5 | 0 | 2 | 9 |
| Region of Enrollment(Participants) | Cohort 1: B-cell ALL (1-17 Years) | Cohort 2: T-Cell ALL (1-17 Years) | Cohort 2: T-Cell ALL (18-30 Years) | Cohort 2: T-Cell Lymphoblastic Leukemia (LL) (1-30 Years) | Total |
|---|---|---|---|---|---|
| BELGIUM | 0 | 1 | 0 | 0 | 1 |
| FRANCE | 0 | 3 | 0 | 2 | 5 |
| GERMANY | 2 | 0 | 0 | 0 | 2 |
| ISRAEL | 0 | 2 | 0 | 0 | 2 |
| ITALY | 2 | 4 | 0 | 0 | 6 |
| NETHERLANDS | 0 | 2 | 0 | 0 | 2 |
| SPAIN | 2 | 5 | 1 | 4 | 12 |
| UNITED KINGDOM | 0 | 3 | 1 | 1 | 5 |
| UNITED STATES | 1 | 4 | 3 | 3 | 11 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2018 to primary completion in Sep 2022, 52 months.
Results were first posted in Oct 2023, 1 year after primary completion.
Of 227 phase 2 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 120. This study's 52 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Daratumumab
Precursor Cell Lymphoblastic Leukemia-Lymphoma →
Janssen Research & Development, LLC →